Icatibant Gp-Pharm (Icatibant)

Icatibant blocks the bradykinin B2 receptor, a key mediator of vasodilation and increased vascular permeability. By competitively antagonising this receptor, the drug prevents bradykinin‑driven edema, providing rapid relief of hereditary angioedema symptoms.

The dose and administration schedule are determined by the prescribing clinician based on the patient’s condition and clinical guidelines. Icatibant is supplied as a ready‑to‑use solution for subcutaneous injection, and the prescriber will specify the exact amount to be administered.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

The main alternative class is plasma‑derived or recombinant C1‑inhibitor concentrates, which replace the deficient protein. Icatibant, as a bradykinin B2 receptor antagonist, directly blocks the downstream mediator of swelling. Both approaches are effective, but icatibant offers a subcutaneous route and rapid onset, while C1‑inhibitor products are administered intravenously.

Icatibant Gp-Pharm should be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

The medication is supplied as a sterile solution for subcutaneous injection. A healthcare professional or trained patient injects the prescribed volume into the subcutaneous tissue, typically in the abdomen or thigh, using the provided pre‑filled syringe or autoinjector device.

Serious risks include hypersensitivity reactions such as rash, urticaria, or anaphylaxis, and rare airway edema that can compromise breathing. Severe hypotension has also been reported. Patients should be monitored after injection and seek immediate medical attention if any of these symptoms develop.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any component of the formulation. Patients with a documented allergy to bradykinin B2 receptor antagonists should also avoid its use. Clinical judgment is required for patients with severe renal or hepatic impairment.